Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphomaBusiness Wire • 02/10/21
Gilead Stock Perks Up After COVID-19 Med Brings In $2.8B In 2020 Sales; Boosts Dividend by 4.4%Benzinga • 02/05/21
Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/05/21
Gilead Stock Pops After Covid Drug Brings In $2.8 Billion In 2020 SalesInvestors Business Daily • 02/04/21
Earnings Results: Gilead stock rallies as it reports $1.9 billion in sales for its COVID-19 drug in Q4Market Watch • 02/04/21
Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 DividendBusiness Wire • 02/04/21
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial ResultsBusiness Wire • 02/04/21
Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender JusticeBusiness Wire • 02/02/21